

Idiopathic Thrombocytopenic Purpura and the Moderna Covid-19 Vaccine



To the Editor:

Recently, it was reported that a physician developed petechiae 3 days after receiving the Pfizer-BioNTech Covid-19 vaccine, was diagnosed with idiopathic thrombocytopenic purpura, and ultimately died of a cerebral hemorrhage.¹ Here, we report a case of idiopathic thrombocytopenic purpura in a 72-year-old woman 1 day after receiving the first dose of the Moderna COVID-19 vaccine.

The day after receiving her vaccination, the patient woke up with a rash, spontaneous oral bleeding, and headache. She denied any history of easy bruising or abnormal bleeding. Her medical history included gout, type 2 diabetes mellitus, and seasonal contact dermatitis. She denied any new medications or changes to her allopurinol and sitagliptin within the last 5 years. She denied any family history of autoimmune disorders.

On examination, she had diffuse petechiae across her arms, legs, and abdomen and hemorrhagic bullae of the gingival mucosa. Laboratory tests were notable for an initial platelet count of 12,000/ μ L, decreasing to 1,000/ μ L within 12 hours of arrival. Other laboratory tests are as shown in [Table 1](#). Of note, normal prothrombin time, activated partial-thromboplastin time, d-dimer, and fibrinogen ruled

out disseminated intravascular coagulation. Further, normal hemoglobin, haptoglobin, lactate dehydrogenase, and peripheral smear without schistocytes were inconsistent with hemolytic uremic syndrome or thrombotic thrombocytopenic purpura. Viral studies, including hepatitis A, B, and C, Epstein-Barr virus, HIV, cytomegalovirus, influenza A and B, and SARS-CoV-2, revealed no evidence of current or prior infection. Parvovirus IgG but not IgM antibodies were present, indicating prior resolved infection. Antinuclear antibody titers were undetectable, making rheumatic etiology less likely.

The patient received an initial 40-mg intravenous dose of dexamethasone and additional doses of 20 mg/day for 3 days thereafter. Intravenous immunoglobulin, aminocaproic acid, and rituximab were administered, and she received multiple platelet transfusions. However, her platelets continued to fluctuate between 1,000/ μ L and 40,000/ μ L. Non-contrast computed tomography of the head was without evidence of intracranial bleeding. Her course was complicated by multiple episodes of melena.

Idiopathic thrombocytopenic purpura postvaccination has been reported in the measles, mumps, and rubella vaccine² and has been associated with the use of attenuated vaccines and vaccine adjuvants, with one review identifying 45% of drug-induced idiopathic thrombocytopenic

Table 1. Clinical laboratory results.

Measure	Reference Range	Hospital Day 1	Hospital Day 3	Hospital Day 5	Hospital Day 8
Hemoglobin (g/dL)	12.0–16.0	13.3	12.2	10.8*	11.1*
Hematocrit (%)	37.0–47.0	41.2	36.3*	33.9*	34.5*
Platelet count (per μ L)	150,000–400,000	12,000*	9,000*	11,000*	1,000*
White-cell count (per μ L)	4,800–10,800	5,320	5,360	3,020*	3,300*
Mean corpuscular volume (fL)	80.0–99.0	92.6	90.5	92.6	92.5
Mean corpuscular hemoglobin (pg)	27.0–31.0	29.9	30.4	29.5	29.8
Mean corpuscular hemoglobin concentration (g/dL)	29.8–35.2	32.3	33.6	31.9	32.2
Red-cell distribution width (%)	12.0–15.0	12.3	12.3	12.0	12.0
Differential count (per μ L)					
Neutrophils	2,100–7,600	3,510	3,630	1600*	2,350
Lymphocytes	1,000–4,900	1,260	1,160	980*	580*
Monocytes	100–1,100	410	480	350	290
Eosinophils	100–400	110	60*	50*	80*
Basophils	0–200	2	1	2	1
Sodium (mmol/L)	136–145	140	141	138	137
Potassium (mmol/L)	3.5–5.1	3.7	4.1	3.9	3.8
Chloride (mmol/L)	98–108	100	104	104	101
Carbon dioxide (mmol/L)	22–29	26	25	28	28
Urea nitrogen (mg/dL)	6.0–23.0	14	19	21	16